Brief: Sprint Bioscience Q1 Operating Loss Widens To SEK 9.5 Million
13/05/2020 06:34
May 13 (Reuters) - Sprint Bioscience AB SPRINT.ST :
* Q1 NET SALES SEK 5.5 MILLION VERSUS SEK 4.6 MILLION YEAR
AGO
* Q1 OPERATING LOSS SEK 9.5 MILLION VERSUS LOSS SEK 6.7
MILLION
YEAR AGO
Source text for Eikon: ID:nWkr4jRCVV
Further company coverage: SPRINT.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Sprint Bioscience AB
See all newsBrief: Sprint Bioscience And Max IV Receive Funding From Vinnova
Brief: Sprint Bioscience Q2 Loss After Tax SEK 16.2 Million
Brief: Sprint Bioscience Announces Deal With Lilly Tunelab
Brief: Sprint Bioscience Partners With Lilly Tunelab For Drug Development
Brief: Sprint Bioscience Q1 Operating Loss SEK 14.3 Mln